Suppr超能文献

射血分数改善的心力衰竭患者的临床特征和长期预后。来自LECRA-HF注册研究的波兰首次经验。

Clinical characteristics and long-term outcomes of patients with heart failure with improved ejection fraction. First Polish experience from LECRA-HF registry.

作者信息

Stępień Konrad, Nowak Karol, Kachnic Natalia, Karcińska Aleksandra, Del Carmen Yika Alicia, Furczyński Jakub, Platschek Michael, Skorupa Maria, Wyleciał Zuzanna, Zalewski Jarosław, Nessler Jadwiga

机构信息

Department of Coronary Artery Disease and Heart Failure, Jagiellonian University Medical College, Kraków, Poland; Department of Thromboembolic Disorders, Jagiellonian University Medical College, Kraków, Poland; "Club 30", Polish Cardiac Society, Warsaw, Poland.

Department of Coronary Artery Disease and Heart Failure, Jagiellonian University Medical College, Kraków, Poland; Department of Thromboembolic Disorders, Jagiellonian University Medical College, Kraków, Poland.

出版信息

Adv Med Sci. 2024 Mar;69(1):132-138. doi: 10.1016/j.advms.2024.02.009. Epub 2024 Mar 4.

Abstract

PURPOSE

Heart failure (HF) with improved ejection fraction (HFimpEF) is a new category of HF introduced in the newest European Society of Cardiology guidelines. However, clinical characteristics and long-term outcomes of HFimpEF patients remain insufficiently elucidated. We sought to characterize Polish HFimpEF patients and determine their long-term mortality.

MATERIAL AND METHODS

Of 1186 patients enrolled in the single-center Lesser Poland Cracovian Heart Failure (LECRA-HF) registry between 2009 and 2019 and hospitalized due to HF decompensation, 340 (28.7%) were those with HF with reduced ejection fraction (HFrEF). Based on follow-up echocardiography, 61 (17.9%) of them were classified as HFimpEF and the remaining as HFnon-impEF.

RESULTS

HFimpEF patients were more frequently females (P ​< ​0.001), had higher baseline left ventricular ejection fraction (LVEF, P ​< ​0.001), had less often a history of diabetes (P ​= ​0.024), severe chronic kidney disease (P ​= ​0.026) or prior myocardial infarction (P ​= ​0.008) than HFnon-impEF patients. By multivariable analysis the HFimpEF diagnosis was independently predicted by baseline NYHA I/II (odds ratio [OR] 2.347, 95% confidence interval [95%CI] 1.020-5.405), non-ischemic etiology (OR 3.096, 95%CI 1.587-6.024), lack of diabetes mellitus (OR 2.016, 95%CI 1.059-3.846) and higher baseline LVEF (OR 1.084, 95%CI 1.042-1.126, per 1%). Within the median 49 (25-77) months all-cause mortality was lower in HFimpEF than in HFnon-impEF (10.8 vs 16.4%/year, P ​= ​0.004).

CONCLUSIONS

Our findings indicate that every sixth Polish patient with HFrEF has a chance to improve LVEF during follow-up and to become a HFimpEF patient. Baseline characteristics of HFimpEF patients are different from HFnon-impEF. Simultaneously, the HFimpEF diagnosis is associated with higher long-term survival.

摘要

目的

射血分数改善的心力衰竭(HFimpEF)是欧洲心脏病学会最新指南中引入的一种新的心力衰竭类型。然而,HFimpEF患者的临床特征和长期预后仍未得到充分阐明。我们旨在描述波兰HFimpEF患者的特征并确定其长期死亡率。

材料与方法

在2009年至2019年期间纳入单中心小波兰克拉科夫心力衰竭(LECRA-HF)登记处并因心力衰竭失代偿住院的1186例患者中,340例(28.7%)为射血分数降低的心力衰竭(HFrEF)患者。根据随访超声心动图,其中61例(17.9%)被分类为HFimpEF,其余为HFnon-impEF。

结果

与HFnon-impEF患者相比,HFimpEF患者女性更为常见(P<0.00),基线左心室射血分数(LVEF)更高(P<0.001),糖尿病病史(P = 0.024)、严重慢性肾病(P = 0.026)或既往心肌梗死(P = 0.008)的发生率更低。通过多变量分析,HFimpEF诊断可由基线纽约心脏协会I/II级(优势比[OR]2.347,95%置信区间[95%CI]1.020-5.405)、非缺血性病因(OR 3.096,95%CI 1.587-6.024)、无糖尿病(OR 2.016,95%CI 1.059-3.846)和更高的基线LVEF(OR 1.084,95%CI 1.042-1.126,每1%)独立预测。在中位49(25-77)个月内,HFimpEF患者的全因死亡率低于HFnon-impEF患者(10.8%对16.4%/年,P = 0.004)。

结论

我们的研究结果表明,每六名波兰HFrEF患者中有机会在随访期间改善LVEF并成为HFimpEF患者。HFimpEF患者的基线特征与HFnon-impEF患者不同。同时,HFimpEF诊断与更高的长期生存率相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验